GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

duvakitug   Click here for help

GtoPdb Ligand ID: 14420

Synonyms: TEV-48574 | TEV48574
Immunopharmacology Ligand
Compound class: Antibody
Comment: Duvakitug (TEV-48574) is a fully human IgG1λ monoclonal antibody that targets TL1A (TNFSF15) [6]. TL1A signalling through its receptor, death receptor 3 (DR3) modulates inflammatory responses and is implicated in profibrotic pathways [1,3-4]. Based on amino acid sequence matches to the heavy and light chain variable regions of duvakitug we suspect this is antibody clone 320-587 in patent US10138296B2 [5].
References
1. Bamias G, Filidou E, Goukos D, Valatas V, Arvanitidis K, Panagopoulou M, Kouklakis G, Daikos GL, Ladas SD, Kolios G. (2017)
Crohn's disease-associated mucosal factors regulate the expression of TNF-like cytokine 1A and its receptors in primary subepithelial intestinal myofibroblasts and intestinal epithelial cells.
Transl Res, 180: 118-130.e2. [PMID:27665176]
2. Banfield C, Rudin D, Bhattacharya I, Goteti K, Li G, Hassan-Zahraee M, Brown LS, Hung KE, Pawlak S, Lepsy C. (2020)
First-in-human, randomized dose-escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF-06480605 in healthy subjects.
Br J Clin Pharmacol, 86 (4): 812-824. [PMID:31758576]
3. Herro R, Miki H, Sethi GS, Mills D, Mehta AK, Nguyen XX, Feghali-Bostwick C, Miller M, Broide DH, Soloff R et al.. (2020)
TL1A Promotes Lung Tissue Fibrosis and Airway Remodeling.
J Immunol, 205 (9): 2414-2422. [PMID:32958689]
4. Perks WV, Singh RK, Jones GW, Twohig JP, Williams AS, Humphreys IR, Taylor PR, Jones SA, Wang ECY. (2016)
Death Receptor 3 Promotes Chemokine-Directed Leukocyte Recruitment in Acute Resolving Inflammation and Is Essential for Pathological Development of Mesothelial Fibrosis in Chronic Disease.
Am J Pathol, 186 (11): 2813-2823. [PMID:27664471]
5. Poulton LD, Pollard M, Doyle AD, Cooksey BA, Pande V, Clarke AW. (2018)
Antibodies that specifically bind to TL1A.
Patent number: US10138296B2. Assignee: Cephalon LLC. Priority date: 16/09/2016. Publication date: 27/11/2018.
6. Solitano V, Jairath V, Ungaro F, Peyrin-Biroulet L, Danese S. (2024)
TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis.
Med, 5 (5): 386-400. [PMID:38574740]